Role of biochemical parameters in prediction of diabetic peripheral neuropathy

Guttikonda, Rajendra; Pothu, Usha Kiran

doi:10.61186/rabms.10.2.169

Volume 10, Issue 2 (4-2024) Journal of Research in Applied and Basic Medical Sciences 2024, 10(2): 169-177 | Back to browse issues page

‎ 10.61186/rabms.10.2.169

Ethics code: 299

Mendeley

Zotero

RefWorks

Guttikonda R, Pothu U K. Role of biochemical parameters in prediction of diabetic peripheral neuropathy. Journal of Research in Applied and Basic Medical Sciences 2024; 10 (2) :169-177
URL: http://ijrabms.umsu.ac.ir/article-1-275-en.html

Role of biochemical parameters in prediction of diabetic peripheral neuropathy

Rajendra Guttikonda

, Usha Kiran Pothu ^*

Professor and HOD, Department of Biochemistry, GSL Medical College, India , usha_123kiran@yahoo.com

Abstract: (959 Views)

Background & Aims: Type 2 diabetes mellitus is the most prevalent form of diabetes seen worldwide. Neuropathy is one of the most common micro-vascular complications of type 2 diabetes mellitus. DPN is considered a main risk factor for diabetic foot leading to amputation, and hence a significant cause of morbidity in diabetes mellitus. Increasing age, longer duration of diabetes and poor glycemic control are well recognized risk factors for DPN. Influence of oxidative stress and corresponding inflammatory changes in tissues in chronic diabetes can be evaluated by certain biochemical parameters. The aim of the present study was to evaluate these biochemical parameters in predicting risk for neuropathy.
Materials & Methods: This is a randomized case control study. This study was done in a tertiary care hospital in Andhra Pradesh. The study was conducted for a period of 4 months from the month of June to October 2022. All the subjects were the patents attending medical OPD and demographic characters were noted. The patients were asked for an overnight fast for collecting blood samples for analyzing parameters like fasting plasma glucose, glycosylated hemoglobin, renal and lipid profile. Institutional ethical committee clearance was taken before starting the study. The study includes a total of 200 subjects with 100 cases of diabetic patients with neuropathies compared with 100 controls of diabetic patients without neuropathy for various biochemical parameters. Statistical analysis was done using graph pad prism software for unpaired t- test and p-value.
Results: There was a significant increase in the levels of fasting plasma glucose (p< 0.0002) glycosylated hemoglobin (p <0.0006), Total Cholesterol (p<0.0017), triglycerides (p <0.0232), creatinine (p<0.0001) and Low-density Lipoprotein cholesterol (LDL-C) (p< 0.0080) in patients with diabetic neuropathy when compared to diabetic patients without neuropathy. And there is significant correlation with duration of diabetes (p<0.0320) and other associated risk factors like hypertension systolic blood pressure (SBP) (p< 0.003) diastolic blood pressure (DBP) (p<0.0001) and Body Mass Index BMI (p<0.002).
Conclusion: From this study it can be seen that regular screening of diabetic patients using biochemical parameters like glycosylated hemoglobin, lipid profile and creatinine and considering the duration of diabetes and other associated risk factors helps in the prediction and prevention of development of neuropathy at an early stage.

Keywords: Diabetic Neuropathy, Duration of Diabetes, Inflammatory Status, Lipid Profile, Oxidative Stress

Full-Text [PDF 272 kb] (183 Downloads) | | Full-Text (HTML) (258 Views)

Type of Study: orginal article | Subject: Other

References

1. Feldman EL, Callaghan BC, Pop-Busui R, Zochodne DW, Wright DE, Bennett DL, et al. Diabetic Neuropathy. Nat Rev Dis Primers 2019;5:41. [DOI:10.1038/s41572-019-0092-1] [PMID]

2. Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: The Rochester Diabetic Neuropathy Study. Neurology 1993; 43:817. [DOI:10.1212/WNL.43.4.817] [PMID]

3. Li L, Chen J, Wang J, Cai D. Prevalence and risk factors of diabetic peripheralneuropathy in Type 2 diabetes mellitus patients with overweight/obese in Guangdongprovince, China. Primary Care Diabetes 2015;9:191-5. [DOI:10.1016/j.pcd.2014.07.006] [PMID]

4. Callaghan BC, Price RS, Feld man EL. Diagnostic and Therapeutic Advances: DistalSymmetric Polyneuropathy. JAMA 2015;314:2172-81. [DOI:10.1001/jama.2015.13611] [PMID] []

5. Qureshi MS, Iqbal M, Zahoor S, Ali J, Javed MU. Ambulatory screening of diabeticneuropathy and predictors of its severity in outpatient settings. J Endocrinol Invest 2017;40:425-30. [DOI:10.1007/s40618-016-0581-y] [PMID]

6. Timar B, Timar R, Gaiță L, Oancea C, Levai C, Lungeanu D. The Impact of DiabeticNeuropathy on Balance and on the Risk of Falls in Patients with Type 2 DiabetesMellitus: A Cross-Sectional Study. PLoS ONE 2016; 11:e0154654. [DOI:10.1371/journal.pone.0154654] [PMID] []

7. Bondor CI, Veresiu IA, Florea B, Vinik EJ, Vinik AI, Gavan NA. Epidemiology ofDiabetic Foot Ulcers and Amputations in Romania: Results of a Cross-Sectional Qualityof Life Questionnaire Based Survey. J Diabetes Res 2016;2016:e5439521. [DOI:10.1155/2016/5439521] [PMID] []

8. Kioskli K, Scott W, Winkley K, Kylakos S, McCracken LM. Psychosocial Factors inPainful Diabetic Neuropathy: A Systematic Review of Treatment Trials and SurveyStudies. Pain Med 2019;20:1756-73. [DOI:10.1093/pm/pnz071] [PMID]

9. Tesfaye S, Chaturvedi N, Eaton SEM, Ward JD, Manes C, Ionescu-Tirgoviste C, et al.Vascular risk factors and diabetic neuropathy. N Engl J Med 2005;352:341-50. [DOI:10.1056/NEJMoa032782] [PMID]

10. Tavakoli M, GogasYavuz D, Tahrani AA, Selvarajah D, Bowling FL, Fadavi H. Diabetic Neuropathy: Current Status and Future Prospects. J Diabetes Res 2017;2017:1-2. [DOI:10.1155/2017/5825971] [PMID] []

11. Yubero-Serrano EM, Delgado-Lista J, Peña- Orihuela P, Perez-Martinez P, Fuentes F,Marin C, and et al. Oxidative stress is associated with the number of components of metabolic syndrome: LIPGENE study. Exp Mol Med 2013;45(6):e28. [DOI:10.1038/emm.2013.53] [PMID] []

12. Jialal I, Devaraj S, Adams-Huet B, Chen X, Kaur H. Increased cellular and circulatingbiomarkers of oxidative stress in nascent metabolic syndrome. J Clin Endocrinol Metab 2012; 97(10):E1844-50. [DOI:10.1210/jc.2012-2498] [PMID]

13. Devaraj S, Goyal R, Jialal I. Inflammation, Oxidative Stress, And The Metabolic Syndrome. US Endocrinol 2008;4(2):32-7. [DOI:10.17925/USE.2008.04.2.32]

14. Abbott CA, Carrington AL, Ashe H, Bath S, Every LC, Griffiths J, et al: The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort Diabet Med 2002;19(5):377-84. [DOI:10.1046/j.1464-5491.2002.00698.x] [PMID]

15. Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ. Chronic painful peripheral neuropathy in an urban community: a controlled comparisonof people with and without diabetes. Diabet Med 2004;21(9):976-82. [DOI:10.1111/j.1464-5491.2004.01271.x] [PMID]

16. Melton LJI, Dyck PJ: Epidemiology: In Diabetic Neuropathy. 2nd edition.Philadelphia: W.B. Saunders; 1999.

17. Jeffcoate WJ, Harding KG: Diabetic foot ulcers. Lancet 2003;361(9368):1545-51. [DOI:10.1016/S0140-6736(03)13169-8] [PMID]

18. Stevens MJ, Feldman EL, and Greene DA: The aetiology of diabetic neuropathy: thecombined roles of metabolic and vascular defects. Diabet Med 1995 12(7):566-79. [DOI:10.1111/j.1464-5491.1995.tb00544.x] [PMID]

19. Gaede P, Vedal P, Parving H, Pederson O. Intensified multifactional intervention inpatients with type 2 diabetes mellitus and microalbuminuria. The steno type 2randomised study. Lancet 1999;353:617-22. [DOI:10.1016/S0140-6736(98)07368-1] [PMID]

20. Klein R, Klein BEK, Moss SE. Correlation of glycemic control to diabetic micro vascularcomplications in diabetes mellitus. Ann Intern Med 1996;124:90-6. [DOI:10.7326/0003-4819-124-1_Part_2-199601011-00003] [PMID]

21. PrzeglLek. Gry z EA, Szermer P, Galicka-lata D, Szczudilik A, The predictors for diabeticneuropathy according to the applied criteria for its diagnosis. Klinika Neurology CNUJ 2002;59(11):881-4.

22. Porta M, Sjoelie AK, Chaturvedi N, Stevens L, Rottiers R, Velglio M, et al .The risk factors for progression to proliferative diabetic retinopathy in the EURODLABProspective complications study, EURODLAB Prospective study group. Diabetologia 2001;44:2203-09. [DOI:10.1007/s001250100030] [PMID]

23. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependentpatients. N Engl J Med 1984;311:89-93. [DOI:10.1056/NEJM198407123110204] [PMID]

24. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H, et al.Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982;1:1430-2. [DOI:10.1016/S0140-6736(82)92450-3] [PMID]

25. Varghese A, Deepa R, Rema M, Mohan V. The prevalance of microalbuminuria in Type2 diabetes mellitus at a diabetes center in southern India. Postgrad Med J 2001;77:399-402. [DOI:10.1136/pmj.77.908.399] [PMID] []

26. Delanaye P, Cavalier E, Pottel H. Serum creatinine: Not so simple! Nephron 2017;136(4):302-8. [DOI:10.1159/000469669] [PMID]

27. Swedko PJ, Clark HD, Paramsothy K, Akbari A. Serum creatinine is an inadequate screening test for renal failure in elderly patients. Arch Intern Med 2003;163(3):356-60. [DOI:10.1001/archinte.163.3.356] [PMID]

28. Estimating the prevalence of renal insufficiency in seniors requiring long-term care. Kidney Int;65:649-53. [DOI:10.1111/j.1523-1755.2004.00412.x] [PMID]

29. Wasserman DH. Four Grams of Glucose. Am J Physiol Endocrinol Metab 2009;296(1):E11-21 [DOI:10.1152/ajpendo.90563.2008] [PMID] []

30. Pouncey A. Excess Sugar Linked To Cancer. Br Dent J 2013;214(4). [DOI:10.1038/sj.bdj.2013.181]

31. Navicharern R. Diabetes Self-Management, Fasting Blood Sugar AndQuality Of Life Among Type 2 Diabetic Patients With Foot Ulcers. J Med Assoc Thailand Chotmaihet Thangphaet 2012;95(2):156-62. [Google Scholar]

32. Tuttle KR, Puhlman ME, Cooney SK, and Short R. Urinary albumin and insulin as thepredictors of coronary artery disease: An angiopathic study. Am J Kidney Dis 1999;34:918-50. [DOI:10.1016/S0272-6386(99)70051-X] [PMID]

33. Wiggin TD, Sullivan KA, Pop-Busui R, Amato A, Sima AA, and Feldman EL: Elevatedtriglycerides correlate with progression of diabetic neuropathy. Diabetes 2009,58(7):1634-40. [DOI:10.2337/db08-1771] [PMID] []

34. Tesfaye S, Harris N, Jakubowski JJ, Mody C, Wilson RM, Rennie IG, Ward JD:Impaired blood flow and arterio-venous shunting in human diabetic neuropathy: a noveltechnique of nerve photography and fluorescein angiography. Diabetologia 1993,36(12):1266-74. [DOI:10.1007/BF00400804] [PMID]

35. Ibrahim S, Harris ND, Radatz M, Selmi F, Rajbhandari S, Brady L, Jakubowski J, WardJD: A new minimally invasive technique to show nerve ischaemia in diabetic neuropathy. Diabetologia 1999;42(6):737-42. [DOI:10.1007/s001250051222] [PMID]

36. Gitlin JD. Transcriptional Regulation of Ceruloplasmin Gene Expression during Inflammation. J Biol Chem 1988;263(13):6281-7. [DOI:10.1016/S0021-9258(18)68783-6] [PMID]

37. Parhi A, Das S, Mahapatra S, Pradhan N, Behera M, Patnaik B, et al. The Level And Role of Interleukin-17 in Patients of Type 2 Diabetes Mellitus with and without Complications. J Diabetes Mellitus 2019;9(4):176-85. [DOI:10.4236/jdm.2019.94017]

38. Doupis J, Lyons TE, Wu S, Gnardellis C, Dinh T, Veves A. Microvascular reactivity andinflammatory cytokines in painful and painless peripheral diabetic neuropathy. JClinEndocrinolMetab 2009;94(6):2157-63. [DOI:10.1210/jc.2008-2385] [PMID] []

39. Ponirakis G, Petropoulos IN, Alam U, Ferdousi M, Asghar O, Marshall A, et al. HypertensionContributes to Neuropathy in Patients With Type 1 Diabetes. Am J Hypertens 2019;32(8):796-803. [DOI:10.1093/ajh/hpz058] [PMID] []